Bridge Laboratories has reached an agreement to build its second preclinical facility in China. This purpose-built, 150,000-sq.-ft. facility will be adjacent to the company's existing laboratory in the Zhongguancun Life Science Park located in Beijing. Construction will begin in 4Q08 and is expected to be complete by 4Q09.
The facility is designed to meet FDA and worldwide regulatory standards, and will provide GLP toxicology, immunology, vaccine, and bioanalytical services, according to the company. This new facility will quadruple Bridge’s available laboratory space in Beijing.
“Bridge is committed to providing quality preclinical services to our customers, and this new facility will enable us to expand our ability to deliver U.S.-level regulatory compliant outsourced discovery and development services in a cost effective manner,” said Tom Oakley, president and chief executive officer of Bridge Laboratories.
Magazine
